Last reviewed · How we verify
NCT01257191
Cellular Inflammation Characterization of Nasal Challenges With Fine and Ultrafine Particles
Phase 1 trial testing Carbon Black in Hypersensitivity, Immediate in 25 participants. Completed in 1 January 2012.
1 January 2012
Quick facts
| Lead sponsor | University of California, Los Angeles |
|---|---|
| Phase | Phase 1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | single |
| Enrollment | 25 |
| Start date | 1 April 2010 |
| Primary completion | 1 January 2012 |
| Estimated completion | 1 January 2012 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Carbon Black — full drug profile →
- Diesel Exhaust Particles — full drug profile →
- Fine Concentrated Ambient Particles — full drug profile →
- Ultrafine Concentrated Ambient Particles — full drug profile →
- Saline
Conditions studied
- Hypersensitivity, Immediate — all drugs for Hypersensitivity, Immediate →
- Atopic Hypersensitivity — all drugs for Atopic Hypersensitivity →
Sponsor
University of California, Los Angeles
Who can join
18 and older, any sex, with Hypersensitivity, Immediate or Atopic Hypersensitivity. Patients with the condition only — healthy volunteers not accepted.
What's being measured
Primary outcomes are the specific endpoints the trial is designed to prove or disprove.
-
The number of inflammatory cells in nasal lavage samples after exposure to 4 different types of particles
Time frame: 6 and 24 hours after nasal challenge
Sponsor's own description
The goal of this study is to see how the type and size of particles found in air pollution affects inflammation in the nose in people who are skin test positive to at least one allergen. It has been observed that pollution makes allergies worse. It has also been suggested that very small particles may affect allergies more than larger particles.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT01257191
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Hypersensitivity, Immediate
Currently open trials in the same condition.
- NCT05420935 — Repertoire and Properties of Anti-drug Antibodies Involved in Immediate Hypersensitivity in the Operating Room · NA · recruiting
Other University of California, Los Angeles trials
Trials by the same sponsor.
- NCT04846517 — rTMS for Aneroxia Nervosa in Youth · NA · not yet recruiting
- NCT06701760 — Sodium Lactate in Severe TBI · Phase 2 · not yet recruiting
- NCT04996667 — Effect of iNO in Patients With Submassive and Massive PE · Phase 2 · withdrawn
- NCT05067387 — Evaluation of Oral THC and CBD in Men and Women · Phase 1 · not yet recruiting
- NCT07534696 — Evaluation of Non-Invasive Pelvic Floor Neuromuscular Stimulation for Urinary Incontinence After Prostatectomy · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT01257191 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of California, Los Angeles
- Last refreshed: 9 January 2017
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01257191.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing